East Ocyon Bio closes $4.2M Seed round led by Aeravti Ventures and Micro Labs
East Ocyon Bio, an allogeneic Cell & Gene Therapy (CGT) startup, on Wednesday, announced the closure of its $4.2 million seed round. The investment round was led by Aeravti Ventures and Micro Labs. The newly raised funds will be utilised to enable several initiatives like pre-clinical testing of CAR-NK and CAR-gamma delta T cell therapies, the creation of a GMP manufacturing facility, and Phase I clinical trials.
Renu Kundu, Founder of East Ocyon Bio, said in a statement, «We are incredibly grateful for the support of Aeravti Ventures and Micro Labs, whose belief in our vision is instrumental in our journey toward clinical validation of this transformative technology.»
Rishabh Singh, Managing Partner at Aeravti Ventures, said in a statement, “India is the cancer capital of the world but receives innovative therapies years after the west. Our partnership with East Ocyon Bio reflects our commitment to supporting impactful organisations that indigenise innovation and create cutting-edge products for the world.”
East Ocyon Bio aims to reshape India’s role in the global biotech landscape, creating an ecosystem where pioneering therapies are developed locally and launched concurrently with international markets.
